glp-1 microdose dosage THE MICRODOSING PROGRAM ✨ What is “Microdosing” GLP-1?

Quality evidence comes from multiple RCTs showing metabolic benefit, though larger long-term PCOS-specific trials continue

Within participants with pre-existing SUDs, initiation of a GLP-1 receptor agonist was associated with reduced risk of SUD related emergency department visits (hazard ratio 0.69 (95% CI 0.61 to 0.78), NRD 8.92 (95% CI 11.59 to 6.25)), SUD related hospital admission (0.74 (0.65 to 0.85), NRD 6.23 (8.73 to 3.74)), and SUD related mortality (0.50 (0.32 to 0.79), NRD 1.52 (2.32 to 0.72)), and associated with reduced risk of the composite endpoint of the three outcomes (0.71 (0.65 to 0.79), NRD 11.79 (14.98 to 8.60)) (fig 6 and supplementary table S11)

l-Carnitine fumarate is synthetically produced

Lee YH, Lee CJ, Lee HS, Choe EY, Lee BW, Ahn CW, Cha BS, Lee HC, Balkau B, Kang ES

I bought this one this time

This creates theoretical concerns about cancer risk that require serious consideration